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Abstract
Background: Advanced machine learning methods combined with large sets of health
screening data provide opportunities for diagnostic value in human and veterinary
medicine.
Hypothesis/Objectives: To derive a model to predict the risk of cats developing
chronic kidney disease (CKD) using data from electronic health records (EHRs) col-
lected during routine veterinary practice.
Animals: A total of 106 251 cats that attended Banfield Pet Hospitals between
January 1, 1995, and December 31, 2017.
Methods: Longitudinal EHRs from Banfield Pet Hospitals were extracted and randomly
split into 2 parts. The first 67% of the data were used to build a prediction model, which
included feature selection and identification of the optimal neural network type and
architecture. The remaining unseen EHRs were used to evaluate the model performance.
Results: The final model was a recurrent neural network (RNN) with 4 features
(creatinine, blood urea nitrogen, urine specific gravity, and age). When predicting
CKD near the point of diagnosis, the model displayed a sensitivity of 90.7% and a
specificity of 98.9%. Model sensitivity decreased when predicting the risk of CKD
with a longer horizon, having 63.0% sensitivity 1 year before diagnosis and 44.2%
2 years before diagnosis, but with specificity remaining around 99%.
Conclusions and clinical importance: The use of models based on machine learning
can support veterinary decision making by improving early identification of CKD.
K E YWORD S
artificial neural network, computer model, feline, machine learning, renal
1 | INTRODUCTION
Chronic kidney disease (CKD) is defined as evidence of functional
impairment or structural damage to the kidney resulting in a reduction
in glomerular filtration rate (GFR). CKD has been described as the
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filtration rate; IRIS, International Renal Interest Society; KNN, k-nearest neighbors algorithm;
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characteristic/precision recall; SDMA, symmetric dimethylarginine; UA/C, urine albumin to
creatinine ratio; UP/C, urine protein to creatinine ratio; USG, urine specific gravity.
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leading cause of mortality in cats over the age of 5,1 with a prevalence
between 8% and 31% reported in geriatric cats.2-4 The etiology of
many feline CKD cases remains unclear, with histological investigations
highlighting nephritis and renal fibrosis that might have resulted from a
range of underlying causes including toxic insults, hypoxia, chronic glo-
merulonephritis, chronic pyelonephritis, upper urinary tract obstruc-
tions, and viral infections.5 The prognosis for cats with CKD depends
on the severity of the disease at the time of diagnosis, with cats identi-
fied at IRIS stage 4 reported to have a 9- to 25-fold shorter life expec-
tancy than those diagnosed at IRIS stage 2.6-8 Early detection of CKD
allows the implementation of care pathways that can slow the progres-
sion of the disease, improving clinical outlook and quality of life, as well
as the avoidance of situations that might cause worsening of kidney
function and acute kidney injury, such as administration of NSAIDs.9
A single, accurate biomarker to assess renal function in clinical
practice does not currently exist.10 Whereas the measurement of GFR
provides a direct assessment of renal function, accepted methods are
technically challenging to implement in clinical settings. Consequently,
serum creatinine remains the standard surrogate for GFR, as part of the
initial diagnosis as well as when staging the disease using recognized
criteria (eg, IRIS11). Further traditional clinical biomarkers, including urea,
proteinuria (an elevated urine protein to creatinine ratio [UP/C]), blood
pressure, and urine specific gravity (USG) might also be referenced as
part of the diagnosis withUP/C and blood pressure used to substage cats
when deciding on the appropriate care pathway. More recently, the use
of serum symmetric dimethylarginine (SDMA) has become popular in
clinical practice, due to early evidence that it is responsive to changes in
renal function sooner than serum creatinine, enabling the early detection
of CKD in non-azotemic cats.12 Additionally, fibroblast growth factor-23
(FGF23) concentration, an important factor in the regulation of phos-
phate and vitamin D metabolism, increases in the circulation before
development of azotemia as GFR declines.13 These more recent CKD
biomarkers represent progress in the development of diagnostic tests to
detect CKD in cats with greater sensitivity or at an earlier stage, but due
to the complex nature of the disease, further research is needed to fully
understand the clinical value of these approaches.
Alongside the search for novel biomarkers, there has been growing
interest in the potential diagnostic value that can be leveraged through
deep analysis of large sets of health screening data collected as part of rou-
tine veterinary practice. Prospective studies using data from cats screened
through veterinary practices in London have demonstrated that routine
measures of renal function do predict the onset of azotemia within
12 months of screening.14 Applying a multivariable logistic regression
approach to longitudinal clinical data, plasma creatinine concentration
together with a measure of proteinuria (either UP/C or urine albumin to
creatinine ratio [UA/C]), successfully differentiate between groups of cats
that develop azotemic CKD within 12 months and those that do not. The
performance of this model in terms of sensitivity and specificity was, how-
ever, insufficient for use in clinical practice, likely due to the small data set
used. Therefore, it seems appropriate to apply the same approach in a big
data setting, building on recent advances in deep machine learning meth-
odology coupled with data availability. In human health care, machine
learning models have been used to assess risk and inform practice
management,15 and predict individual outcomes,16,17 length of stay,18 rec-
ommend treatments,19 and personalized medicine.20,21 Big data, deep
learning strategies therefore offer an opportunity to develop early diagno-
sis algorithms for CKD.
In this study, we used a data set of 106 251 individual cat electronic
health records (EHRs) from primary care veterinary practice to build a
model for CKD risk at a given point in time based on current and past
EHR data. This model was subsequently evaluated with an independent
data set for use at the time of clinical diagnosis as well as for use in the
years before clinical diagnosis. Findings are discussed in terms of clinical
practice and opportunities for new clinical care pathways.
2 | METHODS
2.1 | Data source and initial cleansing
Data were extracted from electronic health records (EHRs) of cats visit-
ing Banfield Pet Hospitals (Vancouver, Washington) between January
1, 1995, and December 31, 2017. At the close of this time period,
Banfield operated over 1000 hospitals in 42 US states. We excluded
information collected from cats before the age of 1.5 and after the age of
22 years. With the further inclusion criterion of at least 3 clinic visits per
cat this yielded a sample of 910 786 cats. The sample contained domes-
tic short-, medium-, and long-haired cats and over 50 pedigree breeds.
Extreme outliers for blood and urine tests—more than 6 SDs above the
maximum of the normal range—were set to missing. Every visit with
blood or urine data was included in the modeling data set. Visits with no
blood or urine datawere only used to assess a cat's diagnosis history.
Each individual EHR included patient demographic data (age, breed,
body weight, and reproductive status), blood and urine test results, and
clinical information (formal diagnosis and unstructured medical notes).
In total, 35 types of information were selected as features for a CKD
prediction model. Data points were primarily collected during or around
hospital visits, with individual visits timestamped meaning that the data
was intrinsically longitudinal.
2.2 | CKD status and age at evaluation T0
Electronic health records in the study data set were classified in 3 CKD
status groups (Figure 1). The first group consists of EHRs with a for-
mally recorded CKD diagnosis (“CKD”). The age of the first CKD diagno-
sis was used as the age at evaluation (T0). For this group, data collected
more than 30 days after the diagnosis was excluded (an additional
30-day window was included to capture serum, blood, or urine test data
that was entered into the database shortly after the diagnosis visit).
Electronic health records without a formal CKD diagnosis, but
with at least 2 CKD-suggesting data points from the following list:
blood creatinine above normal values, USG below normal values, and
“CKD,” “azotemic,” “Royal Canin Veterinary diet Renal” or “Hill's pre-
scription diet k/d” in the medical notes were classified as “probable
CKD.” Whereas the exact reason for a lack of a formal diagnosis
remains uncertain for these EHRs, it is likely that the veterinarian was
unsure about the diagnosis or did not fill in a formal diagnosis for
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procedural reasons. An example of the latter is a diagnosis based on
blood or urine test results received after the hospital visit and policy
not allowing a formal diagnosis without the cat being present. For this
group the age at evaluation (T0) was set to the age at last available
visit, and the complete EHR was used.
All EHRs that were not included in the 2 previous groups and that
have at least 2 years of data (recorded visits) at the end of the EHR to
validate absence of CKD were assigned a “no CKD” status. For these
EHRs, age at evaluation (T0) was set as the age at the last visit minus
2 years, and the last 2 years' data were removed from the EHR.
2.3 | Data sets for model building and testing
The truncated EHRs were further filtered based on their information
content by imposing that the EHR should include at least 2 visits with
accompanying blood creatinine data. This resulted in a data set with
106 251 individual cat EHRs. This data set was randomly split in
2 parts. In total, 70 687 EHRs or approximately 67% of the data was
used to build the CKD prediction model. The remaining 35 564 EHRs
or approximately 33% were used as a test set to evaluate the model
performance. Both data sets were kept separate throughout the anal-
ysis to exclude any bias at the testing stage. Prior to use, missing
information in the blood and urine test data was imputed using all
available blood and urine data but not the CKD status information.
This is needed because neural networks require complete data and
was done separately for model building and test data sets to avoid
any flow of information between the 2 data sets. Only records with at
least some blood or urine data were imputed to fill in missing data.
2.4 | Model building
Prior to use, the model building data set was filtered further ensuring
that only the best characterized EHRs were used for learning. EHRs
with status “probable CKD” were removed as were 7549 “CKD” and
“no CKD” EHRs with “acute kidney injury” or “urinary tract infection”
as comorbidity. This left 53 590 EHRs of which 9586 were “CKD” and
44 004 “no CKD.” To enable the model to work well for early detec-
tion of CKD, this data set was then augmented22 by adding truncated
versions of the original EHRs (last k visits removed with k ranging from
1 to the total number of visits − 1). This enriched the data set with
EHRs having a gap of up to 2 years between the last visit seen by the
model and the time of diagnosis.
The first step toward a CKD prediction model was to select a limited
set of features to be included. Feature selection was conducted by a top-
down and bottom-up wrapper method23 using a standard recurrent neural
network (RNN24 Figure 2) with a 3-5-3 hidden layer structure (see
Supporting Information for background on neural networks). This RNN
model was selected based on exploratory studies (results not shown),
where it outperformed alternatives such as the k-nearest neighbor with
dynamic time warping (KNN-DTW)25 and a long short-termmemory RNN
alternative (LSTM26 Figure 2). The RNNwas implementedwith a tanh acti-
vation function in the hidden layers and softmax for transforming the out-
put layer into a CKD probability score. Backpropagation through time was
used for trainingwith the RMSprop gradient optimization algorithm.Model
performance was evaluated based on the F1 cross-entropy in a 3-fold
cross-validation setup. We used the F1 cross-entropy as a metric because
it balances sensitivity and specificity independent of CKD incidence.
Next, a full model architecture screen was performed with the
selected features for the above-mentioned RNN structure as well as for
a LSTM alternative. For both structures, different configurations of 1 to
5 hidden layers were tested with 3 to 200 nodes per layer. The setup
was the same as above except that 20% dropout was added to avoid
overfitting.27 Evaluation was based on the F1 score in a 10-fold cross-
validation setup.28 Finally the best model configuration was fine-tuned
with respect to the training time in the same cross-validation setup.
2.5 | Model testing
Unbiased model performance was assessed by applying the selected pre-
diction model to the test data set. Predictions were performed for all
EHRs in the “CKD,” “probable CKD,” and “no CKD” groups. Results were
interpreted at the level of the crude model output—the probability of a
CKD diagnosis—as well as after categorization into “no CKD” and “CKD”
using P = .5 as the cutoff point. Categorical results for “CKD” and “no
CKD” groups were used to compute sensitivity (proportion of true posi-
tives, “CKD” status predicted as CKD) and specificity (proportion of true
negatives, “no CKD” predicted as no CKD) estimates, respectively. Cats
designated “probable CKD” could not be assessed for sensitivity or
F IGURE 1 Schematic
representation of CKD status
assignment, EHR data use, and
reference time T0 scaling for
3 hypothetical cat EHR profiles.
CKD* indicates evidence for CKD
in blood or urine analytes or
medical notes. CKD, chronic
kidney disease; EHR, electronic
health record
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specificity as the true diagnosis state was unknown. Confidence intervals
for sensitivity and specificity estimates were calculated using the normal
approximation. Odds ratio tests for the comorbidity analysis (Table 3)
were done with a standard chi-square test.
The ability for the model to predict CKD ahead of the definitive diag-
nosis was evaluated by truncating the EHRs to various time points before
age at diagnosis for the “CKD” group and allowing the model to only see
the truncated data. Sensitivity and specificity estimates were generally
calculated across the entire test data set. For 1 year before diagnosis set-
ting, additional breakdown analyses were performed reporting sensitivity
by year of diagnosis (with the data from 1995 to 2010 pooled) and by
state for the 11 US states with the highest number of EHRs.
2.6 | Software
General data management, statistical analyses, and plots were per-
formed using R version 3.4.329 and imputation was done with the
MissForest package version 1.4.30 Machine learning work was done using
Tensorflow version 1.3 (https://github.com/tensorflow/tensorflow/tree/
r1.3) and interfaced fromwithin Python using Keras Deep Learning library
version 2.0.8 (https://faroit.github.io/keras-docs/2.0.8) run on a
500-core, 4 GB memory per core Dell PowerEdge R730xd cluster
with dual Intel E5-2690 v3 CPUs.
3 | RESULTS
3.1 | Study data set and clinical CKD diagnosis
This study was performed on an extract of 106 251 individual cat EHRs
of Banfield Pet Hospital visits between 1995 and 2017. Demographics
of this sample differentiated by CKD status and summaries of blood and
urine test data at the time of diagnosis are shown in Table 1. The CKD
prevalence in this sample was 17% when based on the “CKD” status
group only, and 42% when including “probable CKD” cats in addition.
F IGURE 2 Schematic representation of recurrent neural network (RNN) approaches. In a standard RNN the input feature data at every visit (here as
an example USG, age, creatinine and blood urea nitrogen[BUN]) are combined in nonlinearways through 2 hidden layerswith 3 and 7 nodes, respectively,
andmergedwith the prior CKDprobability—P(CKD) to yield an updated P(CKD). Theweights and activation functions that define the nonlinear pattern are
the same for every visit. Themodel output is P(CKD) at the last visit. A long short-termmemory (LSTM) approach is conceptually similar but has additional
mechanisms to forget part of the information fromprior visits when combining thesewith the current visit information. CKD, chronic kidney disease
TABLE 1 Demographics and summaries for the study data set. Mean and SD are shown for continuous measures
No CKD Probable CKD CKD
Number of cats 61 239 26 604 18 408
Mean visits per cat 5.4 10.9 8.2
Male to female ratio 1:0.95 1:1.14 1:0.92
Mean (SD) age (years) at T0 6.6 (3.2) 10.7 (3.8) 13.1 (3.7)
Mean (SD) weight (kg) at T0 5.54 (1.49) 5.24 (1.63) 4.49 (1.49)
Mean (SD) blood urea nitrogen (mg/dL) at T0 24.33 (4.27) 32.92 (21.75) 49.85 (27.11)
Mean (SD) creatinine (mg/dL) at T0 1.71 (0.33) 2.19 (1.67) 3.46 (2.13)
Mean (SD) urine SG at T0 1.049 (0.008) 1.036 (0.014) 1.023 (0.011)
Percent missing creatinine values 7% 10% 11%
Percent missing urine SG values 68% 57% 56%
Abbreviations: CKD, chronic kidney disease; SG, specific gravity.
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The prevalence of missing data was approximately 9% for most of the
blood chemistry measures and up to 62% for urine test results, which
are not routinely measured on every visit. Results are very similar after
breakdown in a model building and test data set (Table S4) showing that
these can be used as independent samples of the same population.
As multiple guidelines for the diagnosis of CKD exist, and these
have evolved during the period captured in this study, we explored
how the CKD status as used in this study relates to various diagnostic
measurements routinely assessed when making CKD diagnoses. Cats
with status “CKD” were generally older, and have higher creatinine
levels and lower USG than cats with “no CKD” status (Figure 3). These
results support the quality of the CKD diagnosis within the Banfield
database and provide confidence in the data used to build the model.
For all criteria assessed, there was an overlap in the distributions
between CKD status groups such that any single parameter alone
does not have sufficient discriminatory power for diagnosis. This
intrinsically multifactorial nature of feline CKD presents an ideal set-
ting for prediction models to add clinical value.
To illustrate the data used in this study, we show creatinine,
blood urea nitrogen, and USG for 8 randomly sampled EHRs from
F IGURE 3 Distribution of age at evaluation (T0), creatinine, blood urea nitrogen and urine specific gravity in the study data set differentiated
by CKD status. CKD, chronic kidney disease
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the 3 CKD status groups (Figures 4 and 5). In this small sample, the
“no CKD” EHRs clearly differ from the “probable CKD” and “CKD”
EHRs. At the same time, there is considerable heterogeneity within
the latter groups with quite some changes happening before the
time of diagnosis. This shows that a prediction model should not
only consider multiple factors at the time of diagnosis, but also
include information on these at different time points before diagno-
sis as well.
3.2 | Building a prediction model for CKD
We used a standard RNN with a 3-5-3 hidden layer structure as a
starting point for a prediction model for CKD that acknowledges both
the multifactorial and temporal aspects of CKD diagnosis. Using this
type of model with 35 candidate factors or features was impractical
both for training the model as well as for using it in practice later.
Therefore, we first set out to select the most important features using
a top-down and bottom-up feature selection strategy on the training
data set. This approach showed that model performance in terms of
the cross-entropy score improved by adding features up to 4 and plat-
eaued thereafter (data not shown). As a result, we decided to build a
prediction model with the following features: creatinine, blood urea
nitrogen, USG, and visit age.
With these 4 features, we then determined the best structure for
the hidden layers—number of layers and nodes per layer—for a stan-
dard RNN and a LSTM variant. Results in terms of cross-entropy
F IGURE 4 Randomly picked EHRs for individual cats with CKD status “No CKD” (A,B), “Probable CKD” (C,D) showing the observations for
creatinine, blood urea nitrogen and urine specific gravity as a function of time before diagnosis (T0). CKD, chronic kidney disease
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F IGURE 5 Randomly picked EHRs for individual cats with CKD status “CKD” (A-D) showing the observations for creatinine, blood urea
nitrogen and urine specific gravity as a function of time before diagnosis (T0). CKD, chronic kidney disease
F IGURE 6 F1-score (measure of model performance) as a function of model architecture (number of neurons, indicating complexity) for
recurrent neural network (RNN) and long short-term memory (LSTM) RNN alternative prediction models. A high F1-score indicates a better
performing model
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score (Figure 6) and the notion that higher cross-entropy scores are
better, demonstrated that RNN models were slightly superior to
LSTM models. For the RNN, the simpler models with a small number
of nodes were better than the complex ones. A 2-layer RNN with a
3-7 structure was best. Optimizing this model for training time by
testing different numbers of epochs resulted in a final RNN model
with a 3-7 structure trained over 16 epochs.
3.3 | Detecting CKD near the point of diagnosis
To determine the performance of the CKD model around the time of
diagnosis we applied it on the test data set of 40 205 complete EHRs
that were not used for building the model. The model (Table 2)
showed a sensitivity of 90.7% (6885/7593) based on the status
“CKD” and a specificity of 98.9% (22 534/22 781) based on the status
“no CKD” (Table 2). Predictions for the “probable CKD” group are split
over the “CKD” and “no CKD” predictions. These were not used in the
calculations of sensitivity and specificity as there was no clear clinical
diagnosis for this group.
Distributions of the raw CKD prediction model output (Figure 7)
show similarly clear pictures for “no CKD” and “CKD” status groups:
positioned close to 0 for “no CKD” and close to 1 for “CKD.”
The “probable CKD” status group is more mixed with about 30%
close to 1, likely missed or unrecorded CKD diagnoses, and about
15% close to 0, likely true negatives. The remaining 55% is spread
out between 0 and 1 (the total of the bars adds up to 100%), which
could represent a complicated pathology as well as an early-stage
CKD pattern.
We also evaluated whether misclassification for “no CKD” cats
was linked to specific comorbidities by comparing comorbidity inci-
dence between correctly and incorrectly classified “no CKD” cats. We
found that hyperthyroidism and diabetes mellitus are clearly overrep-
resented in falsely positive classified cats as are hepatopathy and
underweight (Table 3).
The influence of the amount of prior information (number of
visits) on the prediction sensitivity is an important consideration
when evaluating the clinical implementation of such an approach.
The general model performance data does not address this consid-
eration because it is based on the complete sample of EHRs that
includes a range of visits from 1 to 15. Therefore, we next exam-
ined the model sensitivity by number of visits in the EHR before
the visit where the diagnosis was made. We found that sensitivity
clearly benefits from prior information as it increases up to approxi-
mately 90% by using at least 2 visits before the diagnosis
(Figure 8). This shows that historical information contributes to the
prediction of future CKD diagnosis up to a horizon of 2 visits that
is on average 2 years.
3.4 | Using the model for early detection
As the model detects CKD signals at least 2 years before diagnosis for
some cats, we evaluated its use for early prediction of future disease
risk. To achieve this, we truncated EHRs for the “CKD” and “no CKD”
groups at different points before diagnosis (eg, for a 1 year early pre-
diction we removed all information between the diagnosis and 1 year
before) and then evaluated the ability of the model to predict future
onset of CKD. As expected, sensitivity (Figure 9) decreased when
increasing the time between prediction and diagnosis, although of the
TABLE 2 A comparison of number of cats with diagnosed CKD
status against predicted status at T0. “Probable CKD” cats are
included in this table to represent how the model would have
predicted them. No true CKD status is known for these cats
Predicted
“no CKD”
Predicted
“CKD” Total
Status “no CKD” 22 534 247 22 781
Status “probable
CKD”
4223 5608 9831
Status “CKD” 708 6885 7593
Total 27 465 12 740 40 205
Abbreviation: CKD, chronic kidney disease.
F IGURE 7 Distribution of model probability outputs for the
3 different groups predicted at evaluation T0 in the test data
set. A diagnosis probability p(CKD) of greater than 0.5 denotes
a prediction of future CKD risk, and a prediction below 0.5
predicts low future CKD risk for that cat. CKD, chronic kidney
disease
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cats that went on to develop CKD 63.0% were correctly predicted
1 year before diagnosis, 44.2% 2 years before diagnosis, and 23.9% as
far as 3.5 years before clinical diagnosis. Using the 1 year before clini-
cal diagnosis setting as an example, we find that the reported sensitiv-
ity estimates are consistent across the year of diagnosis and across
US states (Tables S5 and S6).
To assess specificity in this context, truncation of the EHRs does not
make sense as cats remain “no CKD” at all earlier visits to clinic. Therefore,
we instead calculated specificity as a function of age at evaluation
(Figure 10). Specificity was consistently above 98% until an age of
11 years and declined thereafter reaching 80% for an age of 15 years. Less
than 20%of veterinary visits in this data setwere above the age of 11.
TABLE 3 Incidence (%) of the 20 most common comorbidities for “No CKD” cats differentiated by their predicted CKD status. The odds ratio
for the comorbidity in “predicted as no CKD” vs “predicted as CKD” is given with an uncorrected P value for a hypothesis test with odds ratio = 1
as null hypothesis
Comorbidity Incidence in predicted “no CKD” (%) Incidence in predicted “CKD” (%) Odds ratio P value
Hyperthyroidism 3.18 22.03 0.116 <.001
Diabetes mellitus 3.37 13.56 0.222 <.001
Hepatopathy 4.63 11.86 0.361 <.001
Underweight 5.8 13.56 0.392 <.001
Murmur 10.32 19.49 0.475 .002
Arthritis 2.23 6.78 0.313 .002
Malaise 11.08 18.64 0.544 .011
Constipation, conservative 3.29 6.78 0.468 .040
Gastroenteritis, conservative 5.77 10.17 0.541 .046
Vomiting, conservative 8.87 13.56 0.620 .078
Inflammatory bowel disease 1.4 3.39 0.406 .079
Crystalluria 5.37 1.69 3.288 .096
Enteritis, conservative 3.29 0.85 3.984 .169
Urinary tract infection 8.02 5.08 1.627 .247
Respiratory disease, upper 11.51 9.32 1.265 .459
Urinary tract disease 4.2 3.39 1.250 .662
Obesity 14.12 15.25 0.913 .724
Inappropriate elimination 6.4 5.93 1.085 .835
Cystitis 21.94 21.19 1.045 .844
Colitis, conservative 6.98 6.78 1.032 .932
Abbreviation: CKD, chronic kidney disease.
F IGURE 8 Model sensitivity with 95% confidence interval as a
function of the number of visits before the time of diagnosis. Note
that confidence intervals increase as there are less EHRs with large
numbers of visits before the time of diagnosis
F IGURE 9 Model sensitivity with 95% confidence intervals as a
function of the time before diagnosis, where the prediction was made
only with the data up to that point
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4 | DISCUSSION
Here we applied advanced computational modeling approaches to a
large, rich data set of EHRs from routine veterinary practice to derive
a model for CKD risk at a given point in time based on current and
past EHR data. We evaluated the performance of this model at the
time of diagnosis, as well as for predicting the risk of cats developing
CKD in the future. From an initial set of 35 candidate features, the
model was refined down to 4 (creatinine, blood urea nitrogen, USG,
and visit age). When predicting CKD near the point of diagnosis, the
model displayed a sensitivity of 90.7% and a specificity of 98.9%.
Interestingly, prediction of CKD risk was possible with 63.0% and
44.2% sensitivity, 1 and 2 years before diagnosis, respectively. Speci-
ficity was over 99% at both advanced time points, which translates
into an extremely low false-positive rate; clearly a key factor when
considering diagnostic performance in clinical settings.
The selected model features that enable the prediction of the
onset of CKD are routinely referenced by veterinarians when CKD
is suspected, and are therefore mechanistically implicated in the dis-
ease etiology. Creatinine and blood urea nitrogen concentrations are
filtration markers and their retention in the circulation can indicate
reduced functional renal mass. As urea more readily crosses lipid
membranes than creatinine and the permeability of the collecting
tubule and duct to urea is selectively increased by antidiuretic hor-
mone, urea is retained in the blood not only when functional kidney
mass is reduced, but also when the body is responding to water defi-
cits and activating mechanisms that conserve water. Inclusion of both
creatinine and urea in this model might help the system avoid falsely
identifying acutely volume depleted animals as having CKD; under
these circumstances, urea would change far more than plasma creati-
nine. Serial monitoring of creatinine is more sensitive in identifying
loss of kidney mass than a single one-off measurement, as creatinine
production can be influenced by nonrenal factors (eg, muscle mass10).
However, the strength of the approach described here is that the
algorithm identifies changes over time in a range of diagnostic
variables that together are indicative of progressive deterioration in
renal function. These often subtle changes over time might be missed
by a veterinarian particularly when the laboratory values have not
moved outside the normal reference range.
USG is a measure of the ability of the kidney to excrete solutes
(mostly waste products) in excess of water, but as the functional kid-
ney mass declines so does the USG. A urine sample from an animal
with normal healthy kidneys can have varying USG depending on
whether the animal needs to conserve or excrete excess water, and
consequently a single assessment is difficult to interpret. Cats often
retain some concentrating ability in IRIS stages 2 and 3 CKD with the
urine only approaching the isosthenuric range as they approach IRIS
stage 4 CKD.31 Interpreting serial data on USG in combination with
plasma creatinine and blood urea nitrogen likely help the model to
identify patterns predictive of falling kidney functional mass and dif-
ferentiate these from natural fluctuations around normal or acute epi-
sodes of dehydration.
Finally, as CKD is primarily a disease of age it is not surprising that
the age of the cat was selected as a feature in the final model. As
highlighted in Table 1, the age profiles of the “no CKD” and “CKD”
groups were different, but there was sufficient overlap to challenge
the model on young as well as old cats. The proportions and age dis-
tributions represent the real distribution of cats seen by Banfield
clinics over the last 20 years. Aging is associated with a range of
chronic conditions and CKD is commonly diagnosed before or at the
same time as hypertension, hyperthyroidism, and diabetes mellitus.32
To understand how the model performed in situations where multiple
diagnoses were present in the EHR, we also evaluated whether mis-
classification for “no CKD” or “CKD” by the model was linked to specific
comorbidities (Table 3). Hyperthyroidism and diabetes mellitus were
overrepresented in false-positive classified cats, most likely due to the
nonspecific nature of the clinical measurements routinely employed to
inform diagnoses across these conditions. It should be noted that the rel-
ative performance of the model was mildly influenced by these cases,
but this is a challenge that veterinarians also encounter in clinical
practice.
The selection of biomarkers presented in this model represents a
combination of variables that gave high predictive accuracy under most
clinical situations. Further work (beyond the scope of this paper) has
highlighted that other biomarkers can be useful in predicting future CKD
when applied using more complex combinations of models. These could,
for example, function by reducing the loss of specificity when predicting
very old cats (Figure 10) or help to separate other comorbidities (Table 3)
more accurately. The other predictive biomarkers identified included
urine protein, urine pH, and white blood cell count. The volume of miss-
ing values related to these variables in the historic data (due to them not
being measured on all visits) has meant that they bring additional noise
to the model as well as enhancing signal. Further testing with more com-
plete data sets might show higher predictive power for these and other
biomarkers.
Recently serum SDMA concentration has been suggested as an
alternative marker of GFR, as it has been shown to correlate closely
with plasma creatinine14 and plasma iohexol clearance in cats.33
F IGURE 10 Model specificity with 95% confidence intervals as a
function of age at diagnosis
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Retrospective analysis of stored longitudinal samples collected as part
of the management of a colony of cats used for nutrition studies
showed that serum concentrations of SDMA increased outside of the
laboratory reference range in 17 of 21 cats that developed azotemia
before an increase in plasma creatinine was detected. On average, ele-
vated SDMA was detected 17 months (range 1.5-48 months) prior to
elevated creatinine.12 The small group of cats and the retrospective
nature of this study likely overestimate the sensitivity and specificity
of SDMA as a predictor of the development of azotemic CKD. SDMA
was not available for much of the time period over which the data
used in the present study were collected. It is interesting to note that
the algorithms devised from these large longitudinal data sets involv-
ing very large numbers of animals presenting to veterinary practices
with a range of different diseases were able to predict the develop-
ment and diagnosis of CKD even 3 years before its onset using data
routinely collected in veterinary practice. Whether longitudinal mea-
surement of SDMA would improve the predictive value of the algo-
rithms developed in the present study warrants further research.
Although EHR data are undoubtedly clinically relevant, using it in
a scientific setting was a challenge. As such, confirming the accuracy
of the CKD diagnosis was an important first step. Data used to build
and validate this model came from a very large number of clinics and vet-
erinarians over a period of more than 20 years and cats with a formal
CKD diagnosis showed blood and urine patterns that are consistent with
currently accepted guidelines (Figure 3); this in itself provides confidence
in the use of these data as a reference point to develop the model.
Defining the health status of the complementary set of cats without a
formal CKD diagnosis was more problematic. A subset of these, those
that were classified as “probable CKD,” had clear indications for CKD in
blood or urine test results or references in the medical notes that suggest
CKD. This group of cats includes those where the veterinarian was
unsure of the diagnosis (most likely because of conflicting information)
or because the cat was in an early stage of the disease, or where for for-
mal reasons they could not be diagnosed. Whereas many case-control
studies typically exclude these somewhat ambiguous patients, thus creat-
ing a wider space between the groups and enhancing the statistical sig-
nificance of findings, we felt the inclusion of these during the training
phase was important to provide additional context that we believe over-
all enhanced the predictive capability of the algorithm. We did not
include this group when computing sensitivity, however, and we are
aware that this could bias our estimates given that it could contain the
more difficult cases to predict. For the other cats without a formal CKD
diagnosis, we imposed a 2-year window with observations and no CKD
to be confident of their “no CKD” status. This could have reduced our
specificity estimates as some might have had very early stage CKD that
was diagnosed more than 2 years later.
The prognosis for cats with CKD depends on the severity of the
disease at the time of diagnosis, with cats identified at IRIS stage
4 reported to have a significantly shorter life expectancy than those
diagnosed at earlier stages.6-8 Early detection of CKD allows the early
implementation of care pathways that can slow the progression of the
disease, improving clinical outlook and quality of life, as well as the
avoidance of situations that might cause worsening of kidney function
and acute kidney injury.9 Consequently work continues to develop
and validate novel diagnostic tools that support clinicians in the early
diagnosis of CKD and represent an improvement in the clinical mea-
sures routinely applied in current veterinary practice (eg, plasma creat-
inine, USG); the limitations of which are well recognized. Here, we
demonstrate overlap in the distributions of a range of routinely
applied diagnostic criteria between cats with and without a CKD diag-
nosis (Figure 3). This highlights the intrinsically multifactorial nature of
CKD, meaning that a single existing clinical parameter alone does not
have sufficient discriminatory power to inform a diagnosis.
The CKD prediction model developed in this study brings several
advantages for veterinary practice. The first is to support the veteri-
narian in making the right diagnosis based on blood and urine test
data currently available for a particular case. Diagnosis is complicated
by the multifactorial nature of CKD, with individual cats often dis-
playing differences in the evolution of these clinical measurements
(Figure 5), most likely due to subtle differences in the etiology and
progression of the disease. One might even argue whether humans
are able to learn all possible patterns because these can be quite dif-
ferent between individual cats (compare, for example, CKD cats in
Figure 5E with Figure 5H). Therefore, having an algorithm highlighting
a risk for CKD can be a very helpful addition to a practicing veterinar-
ian's toolkit. A second advantage is the ability of the algorithm to pre-
dict CKD risk ahead of conventional diagnostic strategies—with a
success (sensitivity) of 44.2% 2 years before diagnosis and of 63.0%
1 year before diagnosis. To enable this early detection, however, it is
important that cats not only regularly (biannual or annual) visit a veter-
inarian, but also that a blood and a urine sample is taken at each visit.
Judging from our database, this is currently not a common occurrence
(Table 1).
The algorithm predicts current/future risk of CKD, as opposed to
IRIS staging that guides the clinician toward appropriate treatment
decisions based on disease progression, a step that occurs following
diagnosis of the disease. Organizations such as IRIS actively promote
the importance of longitudinal health monitoring to detect kidney dis-
ease at an early stage, and we believe this approach strongly supports
this message by highlighting the value in preventative care, not only
supporting the earlier detection of CKD, but in time also presenting
opportunities to proactively monitor a broader range of conditions that
are diagnosed through routine clinical measures. Finally, we recognize
that it is important to develop and validate care pathways based on the
early prediction of CKD, for example, starting a specifically formulated
diet to slow down or halt disease progression. We have initiated a clinical
study to evaluate the benefits of early prediction-based care pathways
versus current best practices to assess whether intervention at the point
the model identifies cats at risk of CKD improves clinical outcome. How-
ever, in the absence of data supporting the efficacy of interventions in
cats with a positive prediction for CKD, it seems appropriate that IRIS
staging guidance for treatment continues to be followed.
In conclusion, here we present evidence for the use of machine learn-
ing to build an algorithm that predicts cats at risk of developing CKD up
to 2 years before diagnosis. The high specificity (>99%) of the algorithm,
coupled with a sensitivity of 63.0%, means that out of 100 cats with a
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prevalence of 15%, 93 cases will be correctly predicted as either not
being diagnosed or being diagnosed with CKD in the next 12 months.
A particular strength of the current approach lies in the use of health
screening data collected as part of routine veterinary practice, meaning
that this model can be rapidly implemented into hospital practice or diag-
nostic laboratory software to directly support veterinarians in making
clinical decisions.
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